Abstract:Objective To evaluate the efficacy of ginsenoside Rg3(GRg3) in the treatment of acute radiation proctitis in rat models. Methods On the 7th day after 21.5Gy irradiation, 100 rats were divided into the control group (normal saline, n=20), GRg3 group (gavage of 20 mg/kg, 40 mg/kg and 80 mg/kg GRg3, n=20 for each dose) and Smecta mixture enema group (n=20). After 2 weeks, all rats were anesthetized with chloral hydrate (3 ml/kg) and approximately 5 ml of blood sample was collected from the abdominal aorta prior to sacrifice. The rectal tissues were taken and prepared for detection of Bax and NF-κB contents and HE staining to observe the pathological changes of the rectal tissues. After the blood samples were centrifuged, the supernatants were collected for ELISA to detect the serum levels of IL-2, IL-6, TNF-α and MPO in each group. Results In the GRg3 group, the serum inflammatory cytokines, serum MPO concentration and the concentration of Bax and NF-κB in the intestinal tissues of rats were decreased along with the increasing dose of GRg3. These parameters in the high-dose GRg3 group were significantly lower than those in the saline group (all P<0.05), whereas did not significantly differ from those in the Smecta mixture enema group (all P>0.05), suggesting that GRg3 exerted good therapeutic effect on acute radiation proctitis in rat models. Conclusions GRg3 can significantly reduce the concentration of inflammatory cytokines, Bax and NF-κB in the intestinal tissues of rat models with acute radiation proctitis, which is more efficacious than the normal saline. GRg3 can be used to treat acute radiation proctitis in rat models.
Hu Tingting,Cai Hongyi. Experimental study of ginsenoside Rg3 in the treatment of acute radiation proctitis in rat models[J]. Chinese Journal of Radiation Oncology, 2019, 28(11): 854-857.
[1] Leadon SA. Repair of DNA damage produced by ionizin gradiation:Aminireview[J]. Semin Radiat Oncol,1996,6(4):295-305. [2] Murdoch C,Muthana M,Lewis CE. Hypoxia regulates macrophage functions in inflammation[J]. J Immunol,2005,175(10):6257-6263. [3] 刘基巍,陈俊霞,于丽华,等. 人参皂甙Rg3和核糖核酸酶抑制因子转基因对小鼠黑色素瘤的抑制作用研究[J]. 中华肿瘤杂志,2004,26(12):22-725. Liu JW,Chen JX,Yu LH,et al. Inhibitory effect of ginsenoside Rg3 and ribonuclease inhibitor transgene on mouse melanoma[J]. Chin J Oncol,2004,26(12):22-725. [4] 杨威,李博,乔世兴,等.人参皂甙Rg3抗鼠源性膀胱癌BBT739黏附、侵袭和肺转移作用的研究[J]. 中国老年学杂志,2005,25(5):571-573. Yang W,Li B, Qiao SX,et al. Study on the adhesion, invasion and lung metastasis of ginsenoside Rg3 against murine bladder cancer BBT739[J]. Chin J Gerontol,2005,25(5):571-573. [5] 侯明晓,敖定椿. 人参皂甙抗心肌缺血-再灌注损伤的作用机制[J]. 中国胸心血管外科临床杂志,2000,7(4):256-259. Hou MX,Ao DC. The mechanism of ginsenosides against myocardial ischemia-reperfusion injury[J]. Chin J Thorac Cardiovasc Surg,2000,7(4):256-259. [6] 黄宗锈,陈冠敏,林蔚. 人参皂甙延缓衰老的实验研究[J]. 实用预防医学,2001,8(5):385. Huang ZX,Chen GM,Lin W. Experimental study on ginsenosides delaying aging[J]. Pract Prev Med,2001,8(5):385. [7] 曾冬香,凌扬,杨全良,等. 中药血管抑制剂人参皂甙 Rg3 联合 FOL-FOX4 方案治疗晚期大肠癌的临床研究[J]. 实用临床医药杂志,2009,13(5):57-58. Zeng DX,Ling Y,Yang QL,et al. Clinical study of traditional Chinese medicine vascular inhibitor ginsenoside Rg3 combined with FOL-FOX4 regimen in the treatment of advanced colorectal cancer[J]. J Clin Med Pract,2009,13(5):57-58. [8] 王金良,孔佩艳,徐葳,等. 人参皂苷 Rg3 抑制急性白血病骨髓基质细胞 HIF-1α及 VEGF 的表达及其机制探讨[J]. 第三军医大学学报,2010,32(7):121-124. DOI:10.16016/j.1000-5404.2010.07.002. Wang JL,Kong PY,Xu W,et al. Study on the expression of HIF-1α and VEGF in bone marrow stromal cells of acute leukemia induced by ginsenoside Rg3 and its mechanism[J]. J Third Mili Med Univ,2010,32(7):121-124. [9] Kang S,Park SJ,Lee AY,et al. Ginsenoside Rg3 promotes inflammation resolution through M2 macrophage polarization[J]. J Ginseng Res,2017,1(2):1. DOI:10.1016/j.jgr.2016.12.012. [10] 王庭富,孟正木. 人参皂甙Rg3对免疫功能的影响[J]. 中国药科大学学报,1999,30(2):133-135. Wang TF,Meng ZM. Effects of Ginsenoside Rg3 on immune function[J]. J Chin Pharmaceut Univ,1999,30(2):133-135. [11] 张仲苗,江波,章荣华,等. 人参皂苷Rg3对小鼠免疫功能的影响[J]. 中药药理与临床,2004,20(6):4-6. Zhang ZM,Jiang B,Zhang RH,et al. Effects of ginsenoside Rg3 on immune function in mice[J]. Pharmacol Clin Chin Med,2004,20(6):4-6. [12] Miliat F,Francois A,Tamarat R,et al. Role of endothelium in radiation induced normal tissue damages[J]. Ann Cardiol Angeiol (Paris),2008,57(3):139-148. DOI:10.1016/j.ancard.2008.02.015. [13] Mao XW. A quantitative study of the effects of ionizing radiation on endothelial cells and capilary like network formation[J]. Technol Cancer Res Treat,2006,5(2):127-134. DOI:10.1177/153303460600500206. [14] Torres J,Danese S. New therapeutic avenues in ulcerative colitis:thinking out of the box[J]. Gut,2013,629(11):1642-1652. DOI:10.1136/gutjnl-2012-303959. [15] 李方,陈阿静,杜鹃,等.共刺激因子在溃疡性结肠炎中的表达及意义[J]. 中华病理学杂志,2010,39(1):19. DOI:10.3760/cma.j.issn.0529-5807.2010.01.006. Li F,Chen AJ,Du J,et al. Expression and significance of costimulatory factors in ulcerative colitis[J]. Chin J Pathol,2010,39(1):19. DOI:10.3760/cma.j.issn.0529-5807.2010.01.006. [16] Yuan Z,Jiang H,Zhu X,et al. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expre-ssion on triple-negative breast cancer[J]. Biomed Pharmacother,2017,89(11):227. DOI:10.1016/j.biopha.2017.02.038. [17] Xie Q,Wen H,Zhang Q,et al. Inhibiting PI3K-AKt signaling pathway is involved in antitumor effects of ginsenoside Rg3 in lung cancer cell[J]. Biomed Pharmacother,2016,85(7):16. DOI:10.1016/j.biopha.2016.11.096. [18] Jerzy G,Franois P,Adriana H,et al. Microvascular function regulates intestinal crypt response to radiation[J]. Cancer Res,2003,63(3):4338-4341. DOI:10.1097/00002820-200308000-00012. [19] 喻卓,陈鹏,杨桂梅,等.20(R)-人参皂苷Rg3对肿瘤坏死因子α诱导血管内皮细胞损伤的保护作用[J]. 岭南心血管病杂志,2011,17(3):198-212. DOI:10.3969/j.issn.1007-9688.2011.03.009. Yu Z,Chen P,Yang GM,et al. Protective effects of 20(R)-ginsenoside Rg3 on vascular endothelial cell injury induced by tumor necrosis factor alpha[J]. J Lingnan Cardiol,2011,17(3):198-212. DOI:10.3969/j.issn.1007-9688.2011.03.009. [20] Bowen JM,Keefe DMK. New pathways for alimentary mucositis[J]. Oncol,2008,907892:1-7. DOI:10.1155/2008/907892.